Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia

International Clinical Psychopharmacology

Volumn 25, Issue 2, 2010, Pages 75-82

  MacFadden, Wayne ^a   Bossie, Cynthia A ^a   Turkoz, Ibrahim ^a   Haskins, John Thomas ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Early illness; Risperidone long acting injectable therapy; Schizophrenia

Indexed keywords

CHOLESTEROL; GLUCOSE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; AGED; AGITATION; AKATHISIA; AMENORRHEA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BACKACHE; BREAST HYPERTROPHY; BREAST TENDERNESS; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GALACTORRHEA; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MENTAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; OBESITY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TOOTH PAIN; TREATMENT OUTCOME; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; ENDPOINT DETERMINATION; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 76349098189     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283347cbf     Document Type: Article

References (42)

1. Almond S, Knapp M, Francois C, Toumi M, Brugha T (2004). Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184:346-351.
2. Barnes TR, Leeson VC, Mutsatsa SH, Watt HC, Hutton SB, Joyce EM (2008). Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry 193:203-209.
3. Birchwood M, Todd P, Jackson C (1998). Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 172:53-59. (Pubitemid 28258899)
4. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, et al. (1995). Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 152:1724-1729.
5. Chouinard G, Ross-Chouinard A, Annable L, Jones B (1980). Extrapyramidal symptom rating scale. Can J Neurol Sci 7:233.
6. Chue P, Emsley R (2007). Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 21:441-448.
7. Coldham EL, Addington J, Addington D (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106: 286-290.
8. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J (2008a). Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 28:210-213.
9. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J (2008b). Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 30:2378-2386.
10. Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER (2005). Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 19:32-38.
11. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. (2004). Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161:692-699.
12. Guy W (1976) Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, Department of Health and Human Service.
13. Kane JM (2006). Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 67 (Suppl 5):9-14.
14. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125-1132.
15. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
16. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. (2004). Comparative effect of atypical and conventional anti-psychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161:985-995.
17. Keith SJ, Kane JM (2003). Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64:1308-1315.
18. Keith SJ, Pani L, Nick B, Emsley R, San L, Turner M, et al. (2004). Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 55:997-1005.
19. Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, et al. (2008). Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 32:1231-1235.
20. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al. (1993). Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50:369-376.
21. Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S (1998). The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J Clin Psychopharmacol 18: 20S-24S.
22. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, et al. (2001). The early stages of schizophrenia: speculations on pathogenesis, pathophy-siology, and therapeutic approaches. Biol Psychiatry 50:884-897.
23. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. (2003). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396-1404.
24. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M (2004). Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 65:1084-1089.
25. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. (2007). Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1050-1060. (Pubitemid 47121394)
26. McGorry PD, Killackey E, Yung A (2008). Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 7:148-156.
27. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E (2005). Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychophar-macol 20:121-130.
28. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101:323-329.
29. Parellada E (2007). Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations. Psychopharmacol Bull 40:82-100.
30. Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, et al. (2005). Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 19:5-14.
31. Perkins DO, Gu H, Boteva K, Lieberman JA (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162:1785-1804.
32. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. (1999a). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241-247. (Pubitemid 29125132)
33. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. (1999b). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 156:544-549. (Pubitemid 29162974)
34. Schmauss M, Sacchetti E, Kahn JP, Medori R (2007). Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 22:85-92.
35. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. (2005). Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 162:947-953.
36. Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. (2006). A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 67:1194-1203.
37. Taylor DM, Young CL, Mace S, Patel MX (2004). Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 65:1076-1083.
38. Taylor DM, Young C, Patel MX (2006). Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 9:685-694.
39. Turner M, Eerdekens E, Jacko M, Eerdekens M (2004). Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 19:241-249. (Pubitemid 38901653)
40. Van Os J, Bossie C, Lasser R (2004). Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 19:229-232.
41. Wyatt RJ (1991). Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophr Res 5:201-202.
42. Wyatt RJ, Henter I (2001). Rationale for the study of early intervention. Schizophr Res 51:69-76.